Please enable JavaScript.
Coggle requires JavaScript to display documents.
Day 1 Breakout Sessions (Comorbidities (Specific Comorbidiites…
Day 1 Breakout Sessions
Molecular/Intracellular
Genetic
-
Is there evidence for a genetic component to response to treatment (eg, SSRIs)?
Should this response genetics be considered for stratification strategies for diagnosis or only patient treatment stratification models?
-
What is the heritability of PTSD? #
-
Within heritability, is there evidence that may indicate treatment response differences? Will this predict comorbidities? Clinical presentation?
Transcriptomic
What do we understand about the relationship of transcriptomic profiles in peripheral blood samples versus CNS?
-
-
Are molecular "risks" present at birth, developmentally regulated, altered by other disorders/conditions, and/or regulated by the trauma - i.e. is there another risk factor altered in one person and not another? # #
Circuit Dysregulation
-
-
-
-
-
-
How does the timing of the trauma alter brain connectivity (i.e. childhood)? #
-
-
-
Relevant to All
-
-
-
Is the evidence provided within this domain intended for:1.Screening/Stratification for Risk
- Diagnosis
- Prognosis
- Treatment Response or predicted treatment response
- Disease activity or severity
-
(Maybe DAy 2) Are there any case studies, i.e. has anyone successfully integrated these models of illness into diagnosis or biotyping? For PTSD? For Other Psych? For anything else?
-
After trauma, there are more consequences than PTSD; what is that we should be looking for in assessment? PTSD? Everything?
-
Everything has been phrased as PTSD - We are either covering chronic neuropsychiatric effects of TBI or not. We will need to answer things from the perspective of applying to both or not.
Duration of Illness, especially chronicity, should be considered across domains.
NOTES
If we do not have a way to measure PTSD, the patient may fall into another bucket/diagnosis and may not get the help they need.
What evidence is there for a biological mechanism for a medical diagnosis?
Whether we need to do a biological basis versus clinician intuition... (INTRO SECTION) Why are we doing this activity.
Psychophysiological
-
-
-
-
How good are psychophys biomakers at identifying PTSD subtypes? How much evidence is there to support their integration into diagnosis?
-
-
-
-
-
-
-
-
Is there enough evidence to support diagnosis or are psychophys markers simply noting population differences?
What is the largest impediment to development right now: The Gold Standard is hard to Measure Against.
-
Comorbidities
-
Is the method by which a comorbidity is diagnosed alter the probability of getting a PTSD diagnosis? #
Similarly, does the availability of treatments for other disorders alter probability of diagnosis of PTSD?
-
-
-
-
-
-
-
-
-
-